keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy breast cancer

keyword
https://www.readbyqxmd.com/read/28231544/ginsenoside-rg3-promotes-cytotoxicity-of-paclitaxel-through-inhibiting-nf-%C3%AE%C2%BAb-signaling-and-regulating-bax-bcl-2-expression-on-triple-negative-breast-cancer
#1
Zuguo Yuan, Hao Jiang, Xinhai Zhu, Xinge Liu, Jinhui Li
Taxane-based chemotherapy regimen is the most effective therapeutic strategy for triple-negative breast cancer (TNBC) which is an aggressive subtype of breast cancer with high rate of recurrence and distant metastasis. Ginsenoside Rg3 is isolated from Panax ginseng with anti-cancer activity against carcinomas. We aim to evaluate the chemosensitizing effects of Ginsenoside Rg3 on TNBC cells and xenograft and explore the underlying mechanism. Human triple-negative breast cancer lines MDA-MB-231, MDA-MB-453 and BT-549 were used...
February 20, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28230773/programmed-death-ligand-1-pd-l1-tumor-expression-is-associated-with-a-better-prognosis-and-diabetic-disease-in-triple-negative-breast-cancer-patients
#2
Gerardo Botti, Francesca Collina, Giosuè Scognamiglio, Federica Rao, Valentina Peluso, Rossella De Cecio, Michela Piezzo, Gabriella Landi, Michelino De Laurentiis, Monica Cantile, Maurizio Di Bonito
Triple Negative Breast Cancers (TNBC) subtype is an aggressive disease with poor clinical outcome. The only treatment available is surgery followed by chemotherapy or radiotherapy. Programmed death-ligand 1 (PD-L1) is a trans-membrane protein expressed on a wide variety of cells including immune cells, epithelial and vascular endothelial cells. Recently, PD-1/PD-L1 pathway signaling was described as an adaptive immune resistance mechanism enacted by the tumor cells to evade the immune response. Its presence on tumor cell membranes, acquired for this reason, through time, is an important prognostic value...
February 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28229982/circulating-free-dna-mutation-associated-with-response-of-targeted-therapy-in-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer
#3
Qing Ye, Fan Qi, Li Bian, Shao-Hua Zhang, Tao Wang, Ze-Fei Jiang
BACKGROUND: The addition of anti-human epidermal growth factor receptor 2 (HER2)-targeted drugs, such as trastuzumab, lapatinib, and trastuzumab emtansine (T-DM1), to chemotherapy significantly improved prognosis of HER2-positive breast cancer patients. However, it was confused that metastatic patients vary in the response of targeted drug. Therefore, methods of accurately predicting drug response were really needed. To overcome the spatial and temporal limitations of biopsies, we aimed to develop a more sensitive and less invasive method of detecting mutations associated with anti-HER2 therapeutic response through circulating-free DNA (cfDNA)...
2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28229358/postmastectomy-radiation-therapy-and-breast-reconstruction-with-autologous-tissue
#4
Yasunobu Terao, Koichiro Taniguchi, Miwako Fujii, So Moriyama
Immediate breast reconstruction is an important tool for patients to accept and overcome their breast cancer, as well as for cosmetic reasons. However, its use in patients who require postmastectomy radiation therapy (PMRT) is not yet clear. The purpose of this study was to analyze the effects of PMRT and reconstruction on each other. The time of initiation of PMRT, the prognosis, and the cosmetic results were investigated in patients who underwent immediate reconstruction using autologous tissue. In the case of delayed reconstruction using autologous tissue after PMRT, radiation damage of the chest skin, design of the flap, and cosmetic results were investigated...
February 22, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28228705/her2-orientated-therapy-in-early-and-metastatic-breast-cancer
#5
REVIEW
Severine Iborra, Elmar Stickeler
Due to the enhanced understanding of molecular oncology and signaling pathways in breast cancer (BC), therapy management has undergone a major transformation, especially with the emergence of treatment tailored to individual disease characteristics. In the case of HER2-positive early or metastatic BC, targeted therapies are well established and remain a major focus of ongoing research. The introduction of anti-HER2 biologicals such as trastuzumab, pertuzumab, and T-DM1 has made targeted and personalized treatment possible and has clearly improved disease-free and overall survival in patients with HER2-positive BC...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228690/human-cytomegalovirus-interleukin-10-enhances-matrigel-invasion-of-mda-mb-231-breast-cancer-cells
#6
Cendy A Valle Oseguera, Juliet V Spencer
BACKGROUND: While some risk factors for breast cancer are well-known, the influence of other factors, particularly virus infection, remains unclear. Human cytomegalovirus (HCMV) is widespread in the general population, and both molecular and epidemiological evidence has indicated links between HCMV and breast cancer. The HCMV protein cmvIL-10 is a potent suppressor of immune function that has also been shown to promote proliferation and migration of breast cancer cells. In this study, the impact of cmvIL-10 on tumor cell invasion through a simulated basement membrane was investigated...
2017: Cancer Cell International
https://www.readbyqxmd.com/read/28228661/feasibility-of-an-exercise-intervention-for-fatigued-breast-cancer-patients-at-a-community-based-cardiac-rehabilitation-program
#7
Stefanie De Jesus, Lyndsay Fitzgeorge, Karen Unsworth, David Massel, Neville Suskin, Harry Prapavessis, Michael Sanatani
PURPOSE: Exercise is beneficial to quality of life after cancer treatment, yet few cancer survivors meet exercise guidelines. Our study sought to determine the feasibility of an oncology rehabilitation exercise program embedded within a cardiac rehabilitation program. METHODS: Patients who rated their fatigue >4/10 after completion of adjuvant chemotherapy for breast cancer were screened for eligibility and the outcomes were assessed (Piper Fatigue Scale, Functional Assessment of Cancer Therapy-Breast [FACT-B], Edmonton Symptom Assessment System, body composition, stress test, and physical activity measurement [accelerometer])...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28228260/chemotherapy-induced-ca-2-release-stimulates-breast-cancer-stem-cell-enrichment
#8
Haiquan Lu, Ivan Chen, Larissa A Shimoda, Youngrok Park, Chuanzhao Zhang, Linh Tran, Huimin Zhang, Gregg L Semenza
Breast cancer stem cells (BCSCs) play a critical role in tumor recurrence and metastasis. Exposure of breast cancer cells to chemotherapy leads to an enrichment of BCSCs. Here, we find that chemotherapy induces the expression of glutathione S-transferase omega 1 (GSTO1), which is dependent on hypoxia-inducible factor 1 (HIF-1) and HIF-2. Knockdown of GSTO1 expression abrogates carboplatin-induced BCSC enrichment, decreases tumor initiation and metastatic capacity, and delays tumor recurrence after chemotherapy...
February 21, 2017: Cell Reports
https://www.readbyqxmd.com/read/28227226/learning-approaches-to-improve-prediction-of-drug-sensitivity-in-breast-cancer-patients
#9
Turki Turki, Zhi Wei, Turki Turki, Zhi Wei, Turki Turki, Zhi Wei
Predicting drug response to cancer disease is an important problem in modern clinical oncology that attracted increasing recent attention from various domains such as computational biology, machine learning, and data mining. Cancer patients respond differently to each cancer therapy owing to disease diversity, genetic factors, and environmental causes. Thus, oncologists aim to identify the effective therapies for cancer patients and avoid adverse drug reactions in patients. By predicting the drug response to cancer, oncologists gain full understanding of the effective treatments on each patient, which leads to better personalized treatment...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28225974/do-you-know-this-syndrome-hand-foot-syndrome
#10
Cintia Santos Braghiroli, Rodrigo Ieiri, Juliana Polizel Ocanha, Rafael Bispo Paschoalini, Hélio Amante Miot
Hand-foot syndrome is a common cutaneous adverse effect associated with certain systemic chemotherapy drugs. It is characterized by erythema, edema, and burning sensation, especially over palmoplantar surfaces. We report the case of an elderly patient undergoing chemotherapy after a breast cancer surgery who developed symptoms two months after the start of the regimen. There are no studies that explore specific therapies. Suggestive therapy include reducing agent dosage, increasing the interval between cycles, or even stopping chemotherapy...
January 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28223672/-influence-of-next-day-administration-of-pegfilgrastim-after-fec100-chemotherapy-in-japanese-with-breast-cancer-on-neutrophil-count
#11
Daichiro Fujiwara, Keiji Mashimo, Kayo Kimura, Akihiro Noda, Kazuo Taki, Hiroshi Yoshibayashi, Tomoya Takeda, Masanobu Tsubaki, Shozo Nishida, Katsuhiko Sakaguchi
Febrile neutropenia(FN)is one of the serious treatment-related toxicities after FEC100(5-fluorouracil 500mg/m2, epiru- bicin 100mg/m2, cyclophosphamide 500 mg/m2)chemotherapy for breast cancer. Granulocyte-colony stimulating factor(GCSF) is used as a support therapy for FN. Thus, we evaluated retrospectively the safety of administering pegfilgrastim the day after FEC100 chemotherapy in Japanese patients with breast cancer as compared with lenograstim. Grade 3 or 4 neutropenia was observed in 91.7% patients after pegfilgrastim administration and in 63...
February 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28223426/resistance-mechanism-against-trastuzumab-in-her2-positive-cancer-cells-and-its-negation-by-src-inhibition
#12
Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
Trastuzumab in combination with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. Several resistance mechanisms against anti-HER2 therapy have been proposed. Src activation has been suggested to be responsible for the resistance of HER2-positive breast cancer. In our study, we generated four trastuzumab-resistant (HR) cancer cell lines from HER2-amplified gastric and biliary tract cancer cell lines (SNU-216, NCI-N87, SNU-2670, and SNU-2773)...
February 21, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28222768/ki-67-as-a-controversial-predictive-and-prognostic-marker-in-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#13
Balázs Ács, Veronika Zámbó, Laura Vízkeleti, A Marcell Szász, Lilla Madaras, Gyöngyvér Szentmártoni, Tímea Tőkés, Béla Á Molnár, István Artúr Molnár, Stefan Vári-Kakas, Janina Kulka, Anna-Mária Tőkés
BACKGROUND: Studies have partly demonstrated the clinical validity of Ki-67 as a predictive marker in the neoadjuvant setting, but the question of the best cut-off points as well as the importance of this marker as a prognostic factor in partial responder/non-responder groups remains uncertain. METHODS: One hundred twenty patients diagnosed with invasive breast cancer and treated with neoadjuvant chemotherapy (NAC) between 2002 and 2013 were retrospectively recruited to this study...
February 21, 2017: Diagnostic Pathology
https://www.readbyqxmd.com/read/28222075/a-pilot-study-of-a-cognitive-behavioral-intervention-for-breast-cancer-survivors
#14
Heather Becker, Ashley M Henneghan, Deborah L Volker, Sabrina Q Mikan
PURPOSE/OBJECTIVES: To test combining a group intervention to build self-efficacy for using compensatory strategies and lifestyle adjustments with brain-training practice to improve cognition.
. DESIGN: A quasiexperimental design.
. SETTING: Texas Oncology, a community oncology practice in Austin.
. SAMPLE: 20 women aged 35-65 years, who had finished chemotherapy at least three months before the study, were within five years of completing all treatment, and had self-reported cognitive concerns...
March 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28222073/a-phase-i-study-of-intravenous-and-oral-rucaparib-in-combination-with-chemotherapy-in-patients-with-advanced-solid-tumours
#15
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, L Rhoda Molife, James Spicer, Veronique Dieras, Patricia Roxburgh, Heidi Giordano, Sarah Jaw-Tsai, Sandra Goble, Ruth Plummer
BACKGROUND: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. METHODS: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1-14) combined with carboplatin (day 1) in 21-day cycles...
February 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28222072/discrepancies-in-central-review-re-testing-of-patients-with-er-positive-and-her2-negative-breast-cancer-in-the-optima-prelim-randomised-clinical-trial
#16
S E Pinder, A F Campbell, J M S Bartlett, A Marshall, D Allen, M Falzon, J A Dunn, A Makris, L Hughes-Davies, R C Stein
BACKGROUND: There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) positive and human epidermal growth factor receptor homologue 2 (HER2) negative. METHODS: The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) was the feasibility phase of a randomised controlled trial to validate the use of multiparameter assay-directed chemotherapy decisions in the UK National Health Service (NHS)...
February 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28221896/accuracy-and-thoroughness-of-treatment-summaries-provided-as-part-of-survivorship-care-plans-prepared-by-two-cancer-centers
#17
Amye J Tevaarwerk, William G Hocking, Jamie L Zeal, Mindy Gribble, Lori Seaborne, Kevin A Buhr, Kari B Wisinski, Mark E Burkard, Douglas A Wiegmann, Mary E Sesto
PURPOSE: Treatment summaries prepared as part of survivorship care planning should correctly and thoroughly report diagnosis and treatment information. METHODS: As part of a clinical trial, summaries were prepared for patients with stage 0 to III breast cancer at two cancer centers. Summaries were prepared per the standard of care at each center via two methods: using the electronic health record (EHR) to create and facilitate autopopulation of content or using manual data entry into an external software program to create the summary...
February 21, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28221688/investigational-drug-combined-with-chemotherapy-improves-response-in-patients-with-brca-mutant-breast-cancer
#18
Carrie Printz
No abstract text is available yet for this article.
March 1, 2017: Cancer
https://www.readbyqxmd.com/read/28221215/experiences-of-patients-with-breast-cancer-of-participating-in-a-lifestyle-intervention-study-while-receiving-adjuvant-chemotherapy
#19
Karianne Vassbakk-Brovold, Anne J Antonsen, Sveinung Berntsen, Christian Kersten, Liv Fegran
BACKGROUND: Lifestyle interventions are suggested to reduce the symptom burden and comorbidities in patients with breast cancer and as an empowerment tool. However, undergoing chemotherapy is associated with low compliance to lifestyle recommendations. Importantly, few studies have documented the experiences of patients with breast cancer of participating in a comprehensive lifestyle intervention study while undergoing curative chemotherapy. OBJECTIVE: The aim of this study was to explore the experiences of patients with breast cancer of participating in an individualized comprehensive lifestyle intervention study focusing on diet, physical activity, mental stress management, and smoking cessation while undergoing curative chemotherapy...
February 17, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28220470/liver-resection-for-her2-enriched-breast-cancer-metastasis-case-report-and-review-of-the-literature
#20
Mai Temukai, Hajime Hikino, Yoshinari Makino, Yoko Murata
Liver metastasis from breast cancer usually results in the development of systemic metastasis. We report a breast cancer patient with an early isolated liver recurrence who survived more than 7 years with no recurrence. She was treated with aggressive HER2-directed chemotherapy and hepatic metastasectomy. Local hepatectomy with effective medical oncological therapy with curative intent is worth trying in patients with breast cancer liver metastasis.
December 2017: Surgical Case Reports
keyword
keyword
55874
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"